CrossMark

The Spectrum of Small Intestinal Bacterial Overgrowth (SIBO)

Eamonn M. M. Quigley[1,2]

Abstract

Purpose of Review To critically review recent (past 3 years) literature on the definition, diagnosis, and management of small intestinal bacterial overgrowth (SIBO).

Recent Findings While various series continue to illustrate the occurrence of SIBO in disease states where well-known risk factors for its occurrence are present (hypochlorhydria, disorders of intestinal structure or motor function, pancreatic insufficiency, and chronic liver disease, for example), the current challenge is in defining the limits of SIBO. Is SIBO truly common among those with "functional" gastrointestinal symptoms where there is no evidence of maldigestion or malabsorption; the original hallmarks of SIBO? Our attempts to address this question continue to be hampered by the limitations of our diagnostic tool kit. There is hope—the application of modern molecular techniques to the study of the small intestinal microbiome, together with some innovative sampling techniques, such as real-time intestinal gas sampling, may soon allow us to truly define the spectrum of SIBO.

Summary SIBO, once removed from its original confines as a cause of malabsorption syndrome, has proven to be an elusive and moving target. Only the most rigorous studies employing validated methodologies will finally corral this mysterious entity.

Keywords Small intestinal bacterial overgrowth · Microbiome · Breath testing · Hydrogen methane · Rifaximin

Introduction

How we Got Here

Any attempt to define the spectrum of small intestinal bacterial overgrowth (SIBO) must begin with a definition of the entity—no easy task. In days of old this was simple and noncontroversial—SIBO was one of the causes of malabsorption and was sought among those who presented with diarrhea, weight loss, steatorrhea and nutritional impairment [1, 2]. Some combination of altered GI anatomy, hypochlorhydria, and dysmotility was the underlying cause

---

This article is part of the Topical Collection on *Small Intestine*

✉ Eamonn M. M. Quigley
equigley@houstonmethodist.org

1 Lynda K and David M Underwood Center for Digestive Disorders, Division of Gastroenterology and Hepatology, Houston Methodist Hospital, Weill Cornell Medical College, Houston, TX, USA

2 Houston Methodist Gastroenterology Associates, 6550 Fannin St, SM 1201, Houston, TX 77030, USA

of these instances of what might be referred to as "classical" SIBO. Based on studies among patients who had undergone gastrointestinal surgery, diagnostic criteria for SIBO were developed on the basis of cultures of jejunal aspirates and a cut-off for the diagnosis of SIBO of $> 10^5$ colony-forming units of bacteria per ml of jejunal juice established. All was well. The arrival of the endoscope, together with an increasing recognition of the relatively cumbersome, invasive, and technically challenging nature of jejunal aspiration prompted a number of innovations. First, gastroenterologists moved their aspirates in an orad direction and performed their cultures on juice obtained from the duodenum—an approach that was subject to contamination and whose diagnostic criteria were never validated. It must be pointed out that recent developments in per-endoscope catheter design have striven to minimize contamination—we look forward to their widespread application and the development of new diagnostic criteria [3]. Second, came the recognition that the intestine was the sole source of a number of gases, and of hydrogen, in particular, that were produced as a by-product of bacterial metabolism of unabsorbed or incompletely absorbed carbohydrates in the diet. In seminal studies, the ability of breath hydrogen assays to provide evidence of carbohydrate malabsorption and to

measure oro-cecal transit opened a new era in noninvasive diagnostics. Not too long afterwards these same breath tests (typically using lactulose as the nonabsorbed carbohydrate substrate) were utilized as tests of SIBO and, in so doing, ushered in what remains a highly controversial expansion of the spectrum of SIBO. Anyone who could swallow a sugary syrup and provide a breath sample could be tested.

Taking our Breath Away

Their apparent simplicity in terms of performance and interpretation, acceptability to the patient and low cost led to the widespread use of breath tests in clinical practice, not only to diagnose SIBO but also to detect carbohydrate intolerance. Were that it was so simple [4]. Of the various breath tests proposed to detect SIBO, two have become by far the most widely employed—the glucose and lactulose breath tests. Nowadays, breath is assayed for both hydrogen and methane following the oral administration of one of these substrates. While considerable progress has been made in the performance of these tests in a manner that minimizes the impact of confounding factors, their interpretation continues to befuddle us. Various diagnostic criteria have been proposed: baseline hydrogen/methane excretion, early rise in gas excretion above baseline, and the presence of a "double peak" with the earlier of these believed to reflect abnormal fermentation of the substrate in a contaminated small intestine with the second, later, peak reflecting the arrival of the substrate in the cecum [5•]. As doubt came to be cast on the "double peak" the "early peak" gained ascendancy. Indeed, the recent North American consensus concluded that "a rise in hydrogen of ≥ 20 ppm above the baseline value by 90 min following substrate ingestion during glucose or lactulose breath test for SIBO was considered positive" [5•]. Despite this interAmerican enthusiasm, the "early peak" has also had its detractors who contend that the "early peak" measures accelerated intestinal transit and not SIBO [6]. Employing simultaneous scintigraphy and breath testing, Yu and colleagues clearly showed that the rise in breath hydrogen regardless of its timing corresponded with the arrival of the substrate in the colon suggesting that rapid transit and not SIBO was responsible for many an "early peak" [6, 7]. In response, the defenders of breath tests assert that the false positive rate for hydrogen breath tests is only 15% and lower for glucose than lactulose tests [8]. This latter assumption that glucose-based tests are free from the influence of transit has also been questioned; Lin and colleagues noting that a radioisotope-labeled bolus of glucose reached the cecum before the appearance of a hydrogen peak [9]. The "early" peak may indeed be too "late" for the small intestine. Sundin and colleagues performed traditional cultures and a detailed analysis using high-throughput sequencing of jejunal aspirates and breath testing in the same

individuals and came to a number of disquieting conclusions [10•]. First, and not surprising, they found that culture grossly underestimated bacterial numbers. Second, and in seeming contradiction of accepted dogma, breath test results and bacterial numbers did not correlate. Third, as they calculated that bacterial overgrowth at and above levels considered diagnostic of SIBO could not produce breath hydrogen levels that met diagnostic thresholds, they deduced that glucose malabsorption and not SIBO was behind a positive breath test [10•]. This study also reveals a major knowledge gap—human small intestinal microbiota. Despite the rapid evolution of our knowledge of various microbiota, our understanding of the normal bacterial population of the small intestine (not to mind how it may be altered in disease states) remains sketchy, to say the least. Access is clearly an issue and one that has led to all but a handful of human studies of gut microbiota being based on fecal sampling—hardly a useful approach to the diagnosis of SIBO [11].

Another recent and exciting innovation, a capsule-based technology that provides real-time measurements of the major intraluminal gases (hydrogen, carbon dioxide, oxygen, and methane) as it moves through the gut, has further shaken the weakened foundation on which breath tests are built [12•]. Their studies, albeit limited at present to experiments in normal volunteers, clearly showed that an oral glucose load of 40 g is, indeed, incompletely absorbed and will, therefore, undergo fermentation in the colon, resulting in a breath hydrogen peak (the infamous "early peak").

Our most commonly relied upon technology is clearly not as reliable as we thought it was—great care needs to be exerted; therefore, in the interpretation of studies that claim to "discover" SIBO as the cause of yet another ailment. New technology will, hopefully, rescue us from this morass—technologies that not only enumerate the normal bacterial population of the small intestine but also measure their various metabolites (other than the gases that we currently measure). How else can one explain how the elderly, widely considered to harbor a less diverse microbiota [13], are so much more likely to develop SIBO [14]. Bacterial function may be more important than mere numbers; in the long run, metabolomics may hold the key to SIBO.

The Prevalence and Spectrum of SIBO Today

Give all that has been said above on the limitations of current diagnostic technologies, it should come as no surprise that there are no reliable data on the true prevalence of SIBO in the general population or even in at-risk groups. Yes, the recent literature again supports the association of SIBO with certain risk factors. Most notable among these are as follows:

1. *Altered anatomy* and, especially, any change that promotes stasis or exposure to colonic contents [15]. Though rare, jejunal diverticulosis is frequently complicated by SIBO [16].

2. *Hypochlorhydria*, including acid suppression. Here, much has been made of the role of proton pump inhibitors; yes, they slightly increase the risk for SIBO [14, 17] but the odds ratio calculated in a recent meta-analysis for SIBO with these widely used medications was only 1.71 [17].

3. *Dysmotility and hypomotility.* Any significant disturbance of small intestinal propulsion [15, 18, 19] be it hypomotility, as in scleroderma [20, 21] or disordered motility, including absence of the migrating motor complex [22]. It has also been suggested that ileocolonic sphincter hypotension may also predispose to SIBO [18]. The relationship between SIBO and motility may be bidirectional as there is some evidence to suggest that excessive production of methane may delay intestinal transit [23].

4. *Immune deficiencies.* SIBO has been described in association with hypogammaglobulinemia, both in inherited and acquired forms, as well as in disorders of cellular immunity, such as human immunodeficiency virus infection (HIV). Interestingly, vagal neuropathy has also been invoked in the causation of SIBO in relation to HIV infection [24].

5. *Small intestinal disease* and, especially, any disease that impairs defense mechanisms and/or promotes stasis, such as radiation enteritis or inflammatory bowel disease (IBD). A number of studies in recent years have revisited the prevalence of SIBO in IBD. SIBO has been described in up to 62% of patients with IBD (both ulcerative colitis and Crohn's disease) and its presence associated with symptoms suggestive of disease activity [25–27] and elevated levels of calprotectin in the stool [26]. Symptoms and indices of disease activity improve with antibiotic therapy alone [25, 27•]. Not surprisingly, SIBO, in Crohn's disease, has been associated with stricturing disease [26]. In a meta-analysis of available studies, the mean prevalence of SIBO in celiac disease was 20% [28] and was associated with persistence of symptoms despite institution of a gluten-free diet.

6. *Multifactorial.* Important examples include SIBO in association with chronic pancreatitis and liver disease.

    (a) In *chronic pancreatitis*, relevant factors include the loss of pancreatic enzymes, a decrease in intestinal motility consequent upon the inflammatory process, the effects of narcotics on gut motility, and the presence, in some instances, of intestinal obstruction. In a meta-analysis, the average prevalence of SIBO among those who suffered from chronic pancreatitis was 36% [29•]. In one study, the presence of SIBO was linked to an alcoholic etiology for chronic pancreatitis, the presence of diabetes, being on a proton pump inhibitor and requiring enzyme replacement therapy [30]; in others, relationships to clinical features were less clear-cut [31, 32]. SIBO has also been described in patients with acute pancreatitis and linked to disease severity [33].

    (b) SIBO has also been frequently documented in association with *liver disease*; another recent meta-analysis estimated an average prevalence of SIBO in chronic liver disease which ranged from 36 to 68% depending on test modality. They also noted similar prevalence rates in those with and without cirrhosis [34•]. In cirrhosis, SIBO has been linked with the occurrence of encephalopathy, both overt and subclinical [35], systemic endotoxemia, and spontaneous bacterial peritonitis [36]. Altered motility, impaired immunity and gut barrier function, as well as changes in the intraluminal milieu are among the factors that might contribute to SIBO in the context of liver disease.

7. *Relationship to SIBO unclear or yet to be defined.* An almost endless list of diseases and disorders has been linked, at one time or another, with SIBO.

    (a) Given the proposed metabolic role of the microbiome and the volume of experimental data to support its contribution to the genesis of *obesity* [37], it should come as no surprise that several studies have examined the prevalence of SIBO in obesity and related disorders, such as type II diabetes and nonalcoholic liver disease [38–44]. Data on the prevalence of SIBO in obesity, per se, are conflicting with one study, employing the lactulose breath hydrogen test, describing SIBO in 89% of obese subjects [40] and another noting an inverse relationship between SIBO and obesity among nonconstipated irritable bowel subjects [45]. Among individuals with type II diabetes the presence of SIBO has been associated with delayed orocecal transit [42]; this relationship does not appear to hold for obesity, in general [40]. SIBO has been shown to increase the risk for NAFLD among obese children [41] and more recent studies [43, 44] provide further support for a role for SIBO in NAFLD and nonalcoholic steatohepatitis (NASH) in adults. Here, mechanistic studies have identified a pathway involving bacterial engagement with Toll-like receptor 4 (TLR-4) and the pro-inflammatory cytokine tumor necrosis factor alpha (TNFα) [37, 44]. The Roux-en-Y gastric bypass procedure appears to increase the occurrence of SIBO in obese subjects

while the adjustable gastric band has no such effect [39]. In a retrospective analysis of breath test database, SIBO was linked to the occurrence and severity of coronary artery disease [46]; a small prospective study provided some evidence to suggest that SIBO might promote atherosclerosis [47].

(b) The advent of the concept of the microbiota–gut–brain axis has provoked interest in the potential role of gut microbes in *neurodegenerative and neuro-inflammatory diseases* [48]. SIBO has been described in association with Parkinson's disease [49–51] and multiple sclerosis [52]. In Parkinson's disease, SIBO prevalence appears to be related to disease severity [49, 50] but, as yet, the impact of SIBO eradication on motor or nonmotor symptoms has not been defined [51].

(c) In the recent literature, SIBO has been described in association with *environmental enteropathy* [53•], *deep venous thrombosis* [54], *Helicobacter pylori infection and its eradication* [55], *familial Mediterranean fever* (where its eradication seems to augment the response to colchicine) [56], and *gall stones* [57], as well as following *partial colectomy* [58, 59] and *cholecystectomy* [60].

8. *Irritable bowel syndrome* (*IBS*). By far the greatest controversy related to SIBO over the past decade and a half has been the proposal that SIBO is linked to irritable bowel syndrome (IBS). In the latest systematic review and meta-analysis, Chen and colleagues calculated a pooled prevalence for SIBO in IBS of 38%; diagnostic modality (breath test vs jejunal aspirate), older age, female sex, and diarrhea predominant symptomatology but not proton pump inhibitor (PPI) use were predictors of SIBO [61•]. Others, documenting this same association found SIBO occurrence was independent of PPI use [62], linked to immune activation [63] but unrelated to gastrointestinal symptomatology or psychiatric comorbidity [63]. Recent studies on therapies effective against SIBO do not help to clarify the issue with the response to antibiotic therapy appearing to be unrelated to the presence or absence of SIBO [64, 65]. Others, indeed, have identified mechanisms, other than its antibiotic effect, whereby rifaximin, which is widely used in both SIBO and IBS, might impact on symptoms [66]. Many factors serve to confound any attempt to interpret the literature on this proposed association: the nonspecific nature of IBS symptoms, the aforementioned limitations of the more commonly used diagnostic methods, variability in patient selection, shortcomings in study design, confounding factors, and the absence of convincing data to indicate that the eradication of SIBO has a long-lasting impact on the natural history of the disease. My own impression is that SIBO is not common in IBS but may be relevant to an IBS subgroup, such as postinfection IBS [67•]. I agree with the conclusion of Aziz, Tornblom, and Simren: "the SIBO-IBS hypothesis lacks convincing evidence but remains under scrutiny" [68•].

Complications of SIBO

The many clinical manifestations of SIBO have been described in detail elsewhere [2]. The recent literature provides further examples of an association between SIBO and malnutrition [69], coagulopathy [70], venous thromboembolism [71], and hyperammonemic encephalopathy [72].

Management

When one searches for high-quality evidence on which to base therapeutic decisions in SIBO one soon finds that the literature is scant and, in general, of low quality. Yes, rifaximin is effective in eradicating SIBO and resolving symptoms [73] and antibiotics are effective in those with scleroderma and SIBO [21], but beyond this, there is little to guide the clinician. Evidence to date suggests that probiotics may promote eradication but do not appear to be effective in preventing SIBO [74].

Summary

SIBO is not a new concept—it began life decades ago as a well-characterized cause of maldigestion and malabsorption. Now, it has morphed into a many-headed monster that seems to engulf all before it. Due to the absence of a true gold standard for the diagnosis of SIBO [75•], all of the literature on its prevalence in, and impact on, various disease states is somewhat suspect. In reviewing the literature from the past few years, I was struck by how similar rates for SIBO prevalence were across a host of disparate disorders (30–40%, typically). Are we merely detecting an epiphenomenon of simply being sick and tested? Responses to treatment are also inconclusive; not only is the evidence base scant but other impacts of our therapies could also be operative. Indeed, it is far from clear what exactly our commonly utilized antibiotics are doing. We desperately need a validated and reliable diagnostic methodology followed by high-quality clinical trials; only then will the true spectrum of SIBO be revealed. The "monster" that we now perceive SIBO to be may be no more than a phantom.

Compliance with Ethical Standards

Conflict of Interest Eamonn M M Quigley reports consultancies with and/or research support from 4D Pharma, Alimentary Health, Allergan, Axon Pharma, Biocodex, Glycyx, Ironwood, Pharmasierra, Salix, Shire, Takeda, Vibrant, and Zeeland.

Human and Animal Rights and Informed Consent   This article does not contain any studies with human or animal subjects performed by any of the authors.

Publisher's Note   Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

Papers of particular interest, published recently, have been highlighted as:
• Of importance

1.   Quigley EMM. Small intestinal bacterial overgrowth: what it is and what it is not. Curr Opin Gastroenterol. 2014;30:141–6.
2.   Quigley EMM. Bacterial overgrowth. In: Camilleri M, Fitz JG, Kalloo AN, Podolsky DK, Shanahan F, Wang TC, editors. Yamada's textbook of gastroenterology. 6th ed. Wiley: Chichester; 2016. p. 1294–304.
3.   Shanahan ER, Zhong L, Talley NJ, Morrison M, Holtmann G. Characterisation of the gastrointestinal mucosa-associated microbiota: a novel technique to prevent cross-contamination during endoscopic procedures. Aliment Pharmacol Ther. 2016;43:1186–96.
4.   Di Stefano M, Quigley EMM. The diagnosis of small intestinal bacterial overgrowth: two steps forward, one step backwards? Neurogastroenterol Motil. 2018;30:e13494.
5.• Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American consensus. Am J Gastroenterol. 2017;112:775–8 A detailed examination of current criteria for the diagnosis of SIBO together with consensus-based recommendations for the performance and interpretation of breath tests.
6.   Yu D, Cheesman F, Vanner S. Combined oro-cecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-cecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut. 2011;60:334–40.
7.   Paterson W, Camilleri M, Simren M, Boeckxstaens G, Vanner SJ. Breath testing consensus guidelines for SIBO: RES IPSA LOCQUITOR. Am J Gastroenterol. 2017;112:1888–9.
8.   Rezaie A, Buresi M, Rao S. Response to Paterson et al. Am J Gastroenterol. 2017;112:1889–92.
9.   Lin EC, Massey BT. Scintigraphy demonstrates high rate of false positive results from glucose breath tests for small bowel bacterial overgrowth. Clin Gastroenterol Hepatol. 2016;124:203–8.
10.• Sundin O, Mendoza-Ladd A, Morales E, Fagan BM, Zeng M, Diaz-Arevalo D, et al. Does glucose-based hydrogen and methane breath test detect bacterial overgrowth in the jejunum? Neurogastroenterol Motil. 2018;30:e13350 **Questions the validity of glucose- based breath tests**.
11. Quigley EMM. Gut microbiome as a clinical tool in gastrointestinal disease management: are we there yet? Nat Rev Gastroenterol Hepatol. 2017;14:315–20.
12.• Berean KJ, Ha N, Ou JZ, Chrimes AF, Grando D, Yao CK, et al. The safety and sensitivity of a telemetric capsule to monitor gastrointestinal hydrogen production in vivo in healthy subjects: a pilot trial comparison to concurrent breath analysis. Aliment Pharmacol Ther. 2018;48:646–54 **Pilot data on a very exciting novel technology which provides real time data on intestinal gas production.**
13. Kundu P, Blacher E, Elinav E, Petterson S. Our gut microbiome: the evolving inner self. Cell. 2017;171:1481–93.
14. Giamarellos-Bourboulis EJ, Pyleris E, Barbatzas C, Pistiki A, Pimentel M. Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage. BMC Gastroenterol. 2016;16:67.
15. Brechmann T, Sperlbaum A, Schmiegel W. Levothyroxine therapy and impaired clearance are the strongest contributors to small intestinal bacterial overgrowth: results of a retrospective cohort study. World J Gastroenterol. 2017;23:842–52.
16. Robey BS, Peery AF, Dellon ES. Small bowel diverticulosis and jejunal perforation in Marfan syndrome. ACG Case Rep J. 2018;5: e5.
17. Su T, Lai S, Lee A, He X, Chen S. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol. 2018;53:27–36.
18. Chander Roland B, Mullin GE, Passi M, Zheng X, Salem A, Yolken R, et al. A prospective evaluation of ileocecal valve dysfunction and intestinal motility derangements in small intestinal bacterial overgrowth. Dig Dis Sci. 2017;62:3525–35.
19. Roland BC, Ciarleglio MM, Clarke JO, Semler JR, Tomakin E, Mullin GE, et al. Small intestinal transit time is delayed in small intestinal bacterial overgrowth. J Clin Gastroenterol. 2015;49:571–6.
20. Tauber M, Avouac J, Benahmed A, Barbot L, Coustet B, Kahan A, et al. Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis patients with gastrointestinal symptoms. Clin Exp Rheumatol. 2014;32(6 Suppl 86):S-82-7.
21. Pittman N, Rawn SM, Wang M, Masetto A, Beattie KA, Larche M. Treatment of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review. Rheumatology (Oxford). 2018;57:1802–11.
22. Deloose E, Tack J. Redefining the functional roles of the gastrointestinal migrating motor complex and motilin in small bacterial overgrowth and hunger signaling. Am J Physiol Gastrointest Liver Physiol. 2016;310:G228–33.
23. Suri J, Kataria R, Malik Z, Parkman HP, Schey R. Elevated methane levels in small intestinal bacterial overgrowth suggests delayed small bowel and colonic transit. Medicine (Baltimore). 2018;97: e10554.
24. Robinson-Papp J, Nmashie A, Pedowitz E, Benn EKT, George MC, Sharma S, et al. Vagal dysfunction and small intestinal bacterial overgrowth: novel pathways to chronic inflammation in HIV. AIDS. 2018;32:1147–56.
25. Greco A, Caviglia GP, Brignolo P, Ribaldone DG, Reggiani S, Sguazzini C, et al. Glucose breath test and Crohn's disease: diagnosis of small intestinal bacterial overgrowth and evaluation of therapeutic response. Scand J Gastroenterol. 2015;50:1376–81.
26. Ricci JERJ, Chebli LA, Ribeiro TCDR, Castro ACS, Gaburri PD, Pace FHDL, et al. Small-intestinal bacterial overgrowth is associated with concurrent intestinal inflammation but not with systemic inflammation in Crohn's disease patients. J Clin Gastroenterol. 2018;52:530–6.
27.• Cohen-Mekelburg S, Tafesh Z, Coburn E, Weg R, Malik N, Webb C, Hammad H, Scherl E, Bosworth BP. Testing and treating small intestinal bacterial overgrowth reduces symptoms in patients with inflammatory bowel disease. Dig Dis Sci. 2018. **Emphasizes the need to consider SIBO in the symptomatic IBD patient.**
28. Losurdo G, Marra A, Shahini E, Girardi B, Giorgio F, Amoruso A, et al. Small intestinal bacterial overgrowth and celiac disease: a systematic review with pooled-data analysis. Neurogastroenterol Motil. 2017;29.

29.• Capurso G, Signoretti M, Archibugi L, Stigliano S, Delle FG. Systematic review and meta-analysis: small intestinal bacterial overgrowth in chronic pancreatitis. United European Gastroenterol J. 2016;4:697–705 **Describes the prevalence of and risk factors for SIBO in chronic pancreatitis.**

30. Ní Chonchubhair HM, Bashir Y, Dobson M, Ryan BM, Duggan SN, Conlon KC. The prevalence of small intestinal bacterial overgrowth in non-surgical patients with chronic pancreatitis and pancreatic exocrine insufficiency (PEI). Pancreatology. 2018;18:379–85.

31. Therrien A, Bouchard S, Sidani S, Bouin M. Prevalence of small intestinal bacterial overgrowth among chronic pancreatitis patients: a case-control study. Can J Gastroenterol Hepatol. 2016;2016:7424831.

32. Kim DB, Paik CN, Sung HJ, Chung WC, Lee KM, Yang JM, et al. Breath hydrogen and methane are associated with intestinal symptoms in patients with chronic pancreatitis. Pancreatology. 2015;15:514–8.

33. Zhang M, Zhu HM, He F, Li BY, Li XC. Association between acute pancreatitis and small intestinal bacterial overgrowth assessed by hydrogen breath test. World J Gastroenterol. 2017;23:8591–6.

34.• Shah A, Shanahan E, Macdonald GA, Fletcher L, Ghasemi P, Morrison M, et al. Systematic review and meta-analysis: prevalence of small intestinal bacterial overgrowth in chronic liver disease. Semin Liver Dis. 2017;37:388–400 **Reaffirms, within the limits of diagnostic methodology, the association between SIBO and chronic liver disease.**

35. Zhang Y, Feng Y, Cao B, Tian Q. The effect of small intestinal bacterial overgrowth on minimal hepatic encephalopathy in patients with cirrhosis. Arch Med Sci. 2016;12:592–6.

36. Victor DW 3rd, Quigley EM. The microbiome and the liver: the basics. Semin Liver Dis. 2016;36:299–305.

37. Quigley EM, Abu-Shanab A, Murphy EF, Stanton C, Monsour HP Jr. The metabolic role of the microbiome: implications for NAFLD and the metabolic syndrome. Semin Liver Dis. 2016;36:312–6.

38. Fialho A, Fialho A, Thota P, McCullough A, Shen B. Higher visceral to subcutaneous fat ratio is associated with small intestinal bacterial overgrowth. Nutr Metab Cardiovasc Dis. 2016;26:773–7.

39. Sabate JM, Coupaye M, Ledoux S, Castel B, Msika S, Coffin B, et al. Consequences of small intestinal bacterial overgrowth in obese patients before and after bariatric surgery. Obes Surg. 2017;27:599–605.

40. Roland BC, Lee D, Miller LS, Vegesna A, Yolken R, Severance E, et al. Obesity increases the risk of small intestinal bacterial overgrowth (SIBO). Neurogastroenterol Motil. 2018;30.

41. Belei O, Olariu L, Dobrescu A, Marcovici T, Marginean O. The relationship between non-alcoholic fatty liver disease and small intestinal bacterial overgrowth among overweight and obese children and adolescents. J Pediatr Endocrinol Metab. 2017;30:1161–8.

42. Rana SV, Malik A, Bhadada SK, Sachdeva N, Morya RK, Sharma G. Malabsorption, orocecal transit time and small intestinal bacterial overgrowth in type 2 diabetic patients: a connection. Indian J Clin Biochem. 2017;32:84–9.

43. Ghoshal UC, Baba CS, Ghoshal U, Alexander G, Misra A, Saraswat VA, et al. Low-grade small intestinal bacterial overgrowth is common in patients with non-alcoholic steatohepatitis on quantitative jejunal aspirate culture. Indian J Gastroenterol. 2017;36:390–9.

44. Kapil S, Duseja A, Sharma BK, Singla B, Chakraborti A, Das A, et al. Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2016;31:213–21.

45. Jung SE, Joo NS, Han KS, Kim KN. Obesity is inversely related to hydrogen-producing small intestinal bacterial overgrowth in non-constipation irritable bowel syndrome. J Korean Med Sci. 2017;32:948–53.

46. Fialho A, Fialho A, Kochhar G, Schenone AL, Thota P, McCullough AJ, et al. Association between small intestinal bacterial overgrowth by glucose breath test and coronary artery disease. Dig Dis Sci. 2018;63:412–21.

47. Ponziani FR, Pompili M, Di Stasio E, Zocco MA, Gasbarrini A, Flore R. Subclinical atherosclerosis is linked to small intestinal bacterial overgrowth via vitamin K2-dependent mechanisms. World J Gastroenterol. 2017 Feb;23:1241–9.

48. Quigley EMM. Microbiota-brain-gut axis and neurodegenerative diseases. Curr Neurol Neurosci Rep. 2017;17:94.

49. Tan AH, Mahadeva S, Thalha AM, Gibson PR, Kiew CK, Yeat CM, et al. Small intestinal bacterial overgrowth in Parkinson's disease. Parkinsonism Relat Disord. 2014;20:535–40.

50. Niu XL, Liu L, Song ZX, Li Q, Wang ZH, Zhang JL, et al. Prevalence of small intestinal bacterial overgrowth in Chinese patients with Parkinson's disease. J Neural Transm (Vienna). 2016;123:1381–6.

51. Vizcarra JA, Wilson-Perez HE, Fasano A, Espay AJ. Small intestinal bacterial overgrowth in Parkinson's disease: tribulations of a trial. Parkinsonism Relat Disord. 2018;54:110–2.

52. Zhang Y, Liu G, Duan Y, Han X, Dong H, Geng J. Prevalence of small intestinal bacterial overgrowth in multiple sclerosis: a case-control study from China. J Neuroimmunol. 2016;301:83–7.

53.• Donowitz JR, Haque R, Kirkpatrick BD, Alam M, Lu M, Kabir M, et al. Small intestine bacterial overgrowth and environmental enteropathy in Bangladeshi children. MBio. 2016;7:e02102–15 **Describes the prevalence and nutritional implications of SIBO in an at-risk population.**

54. Fialho A, Fialho A, Schenone A, Thota P, McCullough A, Shen B. Association between small intestinal bacterial overgrowth and deep vein thrombosis. Gastroenterol Rep (Oxf). 2016;4:299–303.

55. Enko D, Kriegshäuser G. Functional ^{13}C-urea and glucose hydrogen/methane breath tests reveal significant association of small intestinal bacterial overgrowth in individuals with active Helicobacter pylori infection. Clin Biochem. 2017;50:46–9.

56. Verrecchia E, Sicignano LL, La Regina M, Nucera G, Patisso I, Cerrito L, et al. Small intestinal bacterial overgrowth affects the responsiveness to colchicine in familial Mediterranean fever. Mediat Inflamm. 2017;2017:7461426.

57. Kim DB, Paik CN, Song DS, Kim YJ, Lee JM. The characteristics of small intestinal bacterial overgrowth in patients with gallstone diseases. J Gastroenterol Hepatol. 2018;33:1477–84.

58. Deng L, Liu Y, Zhang D, Li Y, Xu L. Prevalence and treatment of small intestinal bacterial overgrowth in postoperative patients with colorectal cancer. Mol Clin Oncol. 2016;4:883–7.

59. Rao SSC, Tan G, Abdulla H, Yu S, Larion S, Leelasinjaroen P. Does colectomy predispose to small intestinal bacterial (SIBO) and fungal overgrowth (SIFO)? Clin Transl Gastroenterol. 2018;9:146.

60. Jung HJ, Paik CN, Chung WC, Lee KM, Yang JM, Choi MG. Small intestinal bacterial overgrowth diagnosed by glucose hydrogen breath test in post-cholecystectomy patients. J Neurogastroenterol Motil. 2015;21:545–51.

61.• Chen B, Kim JJ, Zhang Y, Du L, Dai N. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol. 2018. https://doi.org/10.1007/s00535-018-1476-9. **The latest systematic review on this controversial topic.**

62. Giamarellos-Bourboulis EJ, Pyleris E, Barbatzas C, Pistiki A, Pimentel M. Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage. BMC Gastroenterol. 2016 Jul;16:67.

63. Chu H, Fox M, Zheng X, Deng Y, Long Y, Huang Z, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome: clinical characteristics, psychological factors, and peripheral cytokines. Gastroenterol Res Pract. 2016;2016:3230859.

64. Long SK, Di Palma JA. Does carbohydrate challenge testing pre-dict clinical response in small intestinal bacterial overgrowth? South Med J. 2016;109:296–9.

65. Ghoshal UC, Srivastava D, Misra A, Ghoshal U. A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial over-growth: a randomized, double-blind, placebo-controlled trial. Eur J Gastroenterol Hepatol. 2016;28:281–9.

66. Acosta A, Camilleri M, Shin A, Linker Nord S, O'Neill J, Gray AV, et al. Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome. Clin Transl Gastroenterol. 2016;7:e173.

67.• Ghoshal UC, Gwee KA. Post-infectious IBS, tropical sprue and small intestinal bacterial overgrowth: the missing link. Nat Rev Gastroenterol Hepatol. 2017;14:435–41 **Interesting discussion on the relationships between these disorders, proposing SIBO as the common factor.**

68.• Aziz I, Törnblom H, Simrén M. Small intestinal bacterial over-growth as a cause for irritable bowel syndrome: guilty or not guilty? Curr Opin Gastroenterol. 2017;33:196–202 **A carefully argued critical review of the status of the SIBO-IBS relationship.**

69. Yao J, Chang L, Yuan L, Duan Z. Nutrition status and small intes-tinal bacterial overgrowth in patients with virus-related cirrhosis. Asia Pac J Clin Nutr. 2016;25:283–91.

70. Oliveira RB, Martinelli ALC, Troncon LEA, Elias J Jr. Small intes-tinal bacterial overgrowth (SIBO) and vitamin K-responsive coag-ulopathy: a previously unrecorded association. BMJ Case Rep. 2018. https://doi.org/10.1136/bcr-2017-223531.

71. Cheng X, Zhang L, Xie NC, Xu HL, Lian YJ. Association between small-intestinal bacterial overgrowth and deep vein thrombosis in patients with spinal cord injuries. J Thromb Haemost. 2017;15: 304–11.

72. McIntosh S, Medjoub K, Deans K, Sexton S. Hyperammonaemic encephalopathy following an uncomplicated surgery. BMJ Case Rep 2017. https://doi.org/10.1136/bcr-2017-221458.

73. Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther. 2017;45:604–16.

74. Zhong C, Qu C, Wang B, Liang S, Zeng B. Probiotics for preventing and treating small intestinal bacterial overgrowth: a meta-analysis and systematic review of current evidence. J Clin Gastroenterol. 2017;51:300–11.

75.• Adike A, DiBaise JK. Small intestinal bacterial overgrowth: nutri-tional implications, diagnosis, and management. Gastroenterol Clin N Am. 2018;47:193–208 **An up-to-date review of SIBO management.**